-
公开(公告)号：US20120076728A1
公开(公告)日：2012-03-29
申请号：US13263069
申请日：2010-04-07
申请人： Anna M. Wu , Vania E. Kenanova , Tove Olafsen
发明人： Anna M. Wu , Vania E. Kenanova , Tove Olafsen
CPC分类号： C07K14/765 , A61K38/00 , A61K47/61 , A61K47/6889 , A61K51/1048 , C07K16/42 , C07K19/00 , C07K2319/30 , C07K2319/33 , C12N15/115 , C12N2310/16
摘要： This invention provides constructs comprising a protein scaffold, wherein the scaffold comprises Domain III, Domain IIIa, or Domain IIIb of human serum albumin or a polypeptide having substantial sequence identity to the Domain III, the Domain IIIa, or the Domain IIIb; and a targeting moiety in covalent linkage to the protein scaffold; and a therapeutic moiety and/or an imaging moiety in covalent linkage to the protein scaffold. The scaffold can be modified to tune the serum pharmacokinetics of the construct. In addition to methods of making the constructs, therapeutic, imaging and diagnostic uses of the constructs are also provided.
摘要翻译： 本发明提供了包含蛋白质支架的构建体，其中所述支架包含人血清白蛋白的III区，IIIa区或IIIb区，或与III，Domain IIIa或Domain IIIb具有实质序列同一性的多肽; 和与蛋白质支架共价连接的靶向部分; 和与蛋白质支架共价连接的治疗部分和/或成像部分。 可以修饰支架以调节构建体的血清药代动力学。 除了制备构建体的方法之外，还提供了构建体的治疗，成像和诊断用途。
-
公开(公告)号：US20100069616A1
公开(公告)日：2010-03-18
申请号：US12537145
申请日：2009-08-06
IPC分类号： C07K16/00
CPC分类号： G01N33/57492 , A61K49/0058 , A61K49/0067 , C07K16/32 , G01N33/57415 , G01N33/57434 , G01N33/588
摘要： Conjugates of a C-terminal modified diabody and a nanoparticle are provided in which the C-terminal modification introduces a cysteine residue at a C-terminus of the diabody and the diabody is covalently linked to the nanoparticle via a heterobiofunctional linker attached to the introduced cysteine residue.
摘要翻译： 提供C末端修饰的双抗体和纳米颗粒的缀合物，其中C-末端修饰在双抗体的C末端引入半胱氨酸残基，并且双抗体通过连接到引入的半胱氨酸的异功能性接头与纳米颗粒共价连接 残留物
-
公开(公告)号：US09701754B1
公开(公告)日：2017-07-11
申请号：US12788477
申请日：2010-05-27
CPC分类号： C07K16/30 , A61K39/39558 , A61K2039/505 , C07K16/00 , C07K16/3007 , C07K16/46 , C07K2317/626 , C07K2317/64 , C07K2317/90 , C07K2319/00
摘要： The present invention provides recombinant antibody fragments which include a variable domain which has been modified by the addition of a tail sequence to its C-terminal end. The tail sequence comprises a terminal cysteine residue and an amino acid spacer and does not substantially affect the fragment's target-binding affinity. The present invention also provides pharmaceutical compositions comprising the described antibody fragments and a pharmaceutically acceptable carrier and methods of delivering an agent to cells of interest in a subject using the fragments as delivery vehicles. The invention further provides compositions comprising the described antibody fragments for the in vitro detection and measurement of target molecules which bind to the fragments and method of determining the presence or amount of such targets in a biological sample by contacting the sample with such compositions.
-
公开(公告)号：US20120283418A1
公开(公告)日：2012-11-08
申请号：US13554306
申请日：2012-07-20
IPC分类号： C07K16/00
CPC分类号： C07K16/30 , A61K39/39558 , A61K2039/505 , C07K16/00 , C07K16/3007 , C07K16/46 , C07K2317/626 , C07K2317/64 , C07K2317/90 , C07K2319/00
摘要： The present invention provides recombinant antibody fragments which include a variable domain which has been modified by the addition of a tail sequence to its C-terminal end. The tail sequence comprises a terminal cysteine residue and an amino acid spacer and does not substantially affect the fragment's target-binding affinity. The present invention also provides pharmaceutical compositions comprising the described antibody fragments and a pharmaceutically acceptable carrier and methods of delivering an agent to cells of interest in a subject using the fragments as delivery vehicles. The invention further provides compositions comprising the described antibody fragments for the in vitro detection and measurement of target molecules which bind to the fragments and method of determining the presence or amount of such targets in a biological sample by contacting the sample with such compositions.
摘要翻译： 本发明提供重组抗体片段，其包括通过向其C末端添加尾序列而被修饰的可变结构域。 尾序列包含末端半胱氨酸残基和氨基酸间隔基，并且基本上不影响片段的靶结合亲和力。 本发明还提供包含所述抗体片段和药学上可接受的载体的药物组合物，以及使用片段作为递送载体将试剂递送至受试者感兴趣的细胞的方法。 本发明还提供了包含所述抗体片段的组合物，用于体外检测和测量结合片段的靶分子，以及通过使样品与这些组合物接触来确定生物样品中这些靶的存在或量的方法。
-
5.发明授权Engineered anti-CD20 antibody fragments for in vivo targeting and therapeutics 失效用于体内靶向和治疗的工程化抗CD20抗体片段公开(公告)号：US07727525B2
公开(公告)日：2010-06-01
申请号：US11741253
申请日：2007-04-27
申请人： Anna M. Wu , Tove Olafsen , Andrew A. Raubitschek
发明人： Anna M. Wu , Tove Olafsen , Andrew A. Raubitschek
IPC分类号： A61K51/10 , A61K49/00 , A61K39/395
CPC分类号： C07K16/2887 , A61K51/1027 , C07K2317/622 , C07K2319/30
摘要： The present invention provides anti-CD20 antibody fragments for use as in vivo imaging probes and as therapeutic moieties for the diagnosis and treatment of NHL.
摘要翻译： 本发明提供用作体内成像探针的抗CD20抗体片段和用于诊断和治疗NHL的治疗部分。
-
公开(公告)号：US09765155B2
公开(公告)日：2017-09-19
申请号：US13554306
申请日：2012-07-20
IPC分类号： A61K39/00 , C07K16/46 , C07K16/00 , C07K16/30 , A61K39/395
CPC分类号： C07K16/30 , A61K39/39558 , A61K2039/505 , C07K16/00 , C07K16/3007 , C07K16/46 , C07K2317/626 , C07K2317/64 , C07K2317/90 , C07K2319/00
摘要： The present invention provides recombinant antibody fragments which include a variable domain which has been modified by the addition of a tail sequence to its C-terminal end. The tail sequence comprises a terminal cysteine residue and an amino acid spacer and does not substantially affect the fragment's target-binding affinity. The present invention also provides pharmaceutical compositions comprising the described antibody fragments and a pharmaceutically acceptable carrier and methods of delivering an agent to cells of interest in a subject using the fragments as delivery vehicles. The invention further provides compositions comprising the described antibody fragments for the in vitro detection and measurement of target molecules which bind to the fragments and method of determining the presence or amount of such targets in a biological sample by contacting the sample with such compositions.
-
公开(公告)号：US08318906B2
公开(公告)日：2012-11-27
申请号：US12682032
申请日：2008-10-08
申请人： Jonathan Braun , Lynn K. Gordon , Kaori Shimizaki , Madhuri Wadegra-Dhawan , Kathy A. Kelly , Anna M. Wu
发明人： Jonathan Braun , Lynn K. Gordon , Kaori Shimizaki , Madhuri Wadegra-Dhawan , Kathy A. Kelly , Anna M. Wu
IPC分类号： C07K16/00 , C12P21/08 , A61K39/395 , G01N33/566
CPC分类号： C07K16/30 , A61K39/39558 , A61K45/06 , C07K16/125 , C07K16/28 , C07K2316/96 , C07K2317/21 , C07K2317/34 , C07K2317/52 , C07K2317/622 , C07K2317/73 , C07K2317/76 , C07K2319/00 , A61K2300/00
摘要： The present invention provides methods and compositions useful in the treatment or prevention of Chlamydia infections and cancer. The methods and compositions inhibit the entry of Chlamydia into a host cell expressing EMP2 by interfering with the interaction between the Chlamydia and EMP2. The methods and compositions target cancers which express or overexpress EMP2 nucleic acids and polypeptides by targeting EMP2.
摘要翻译： 本发明提供了用于治疗或预防衣原体感染和癌症的方法和组合物。 方法和组合物通过干扰衣原体和EMP2之间的相互作用来抑制衣原体进入表达EMP2的宿主细胞。 方法和组合物靶向通过靶向EMP2表达或过表达EMP2核酸和多肽的癌症。
-
公开(公告)号：US20120178141A1
公开(公告)日：2012-07-12
申请号：US13426790
申请日：2012-03-22
CPC分类号： C12Q1/66
摘要： Briefly described, embodiments of this disclosure include polynucleotides that encode mutant Cnidarian luciferases that exhibit modulated properties as compared to the corresponding wild-type luciferases, and the modulated properties include at least one of: modulated stability; enhanced light output; and modulated emission maximum. Embodiments of the present disclosure also include polypeptides or fragments thereof encoded by the polynucleotides, constructs including the polynucleotide, expression cassettes, cells, methods of producing the polynucleotides and polypeptides, antibodies, transgenic cells and/or animals, kits, and the like.
-
公开(公告)号：US08088908B2
公开(公告)日：2012-01-03
申请号：US11432304
申请日：2006-05-10
申请人： Mark A. Sherman , Anna M. Wu , Robert E. Reiter
发明人： Mark A. Sherman , Anna M. Wu , Robert E. Reiter
IPC分类号： C07H21/04
CPC分类号： C07K16/3069 , A61K2039/505 , C07K2317/24 , C07K2317/565
摘要： Prostate stem cell antigen (PSCA) is expressed in the majority of prostate cancer patients, making it an ideal target for cancer immunotherapy. Murine monoclonal antibody 1G8 binds to PSCA with nanomolar affinity, but its efficacy as a therapeutic agent is limited by the generation of a HAMA response. The present invention discloses humanized 1G8 antibodies in which the majority of the mouse-derived epitopes have been removed. These humanized antibodies bind PSCA with high affinity and specificity, and have been shown to reduce human bladder tumor take in a nude mouse model. These characteristics make the humanized antibodies of the present invention attractive agents for the treatment and detection of tumors expressing PSCA.
摘要翻译： 前列腺干细胞抗原（PSCA）在大多数前列腺癌患者中表达，使其成为癌症免疫治疗的理想靶标。 鼠单克隆抗体1G8以纳摩尔亲和力结合PSCA，但其作为治疗剂的功效受到HAMA反应的产生的限制。 本发明公开了大部分小鼠来源的表位已被除去的人源化1G8抗体。 这些人源化抗体以高亲和力和特异性结合PSCA，并已显示可以减少人膀胱肿瘤的裸鼠模型。 这些特征使得本发明的人源化抗体用于治疗和检测表达PSCA的肿瘤的吸引剂。
-
公开(公告)号：US20110229955A1
公开(公告)日：2011-09-22
申请号：US13070665
申请日：2011-03-24
CPC分类号： C12Q1/66
摘要： Briefly described, embodiments of this disclosure include polynucleotides that encode mutant Cnidarian luciferases that exhibit modulated properties as compared to the corresponding wild-type luciferases, and the modulated properties include at least one of: modulated stability; enhanced light output; and modulated emission maximum. Embodiments of the present disclosure also include polypeptides or fragments thereof encoded by the polynucleotides, constructs including the polynucleotide, expression cassettes, cells, methods of producing the polynucleotides and polypeptides, antibodies, transgenic cells and/or animals, kits, and the like.
摘要翻译： 简要描述，本公开的实施方案包括编码与相应的野生型萤光素酶相比表现出调节特性的突变型雀巢萤光素酶的多核苷酸，并且调节的性质包括以下至少一种：调节的稳定性; 增强光输出; 并调制发射最大值。 本公开的实施方案还包括由多核苷酸编码的多肽或其片段，包括多核苷酸的构建体，表达盒，细胞，产生多核苷酸和多肽的方法，抗体，转基因细胞和/或动物，试剂盒等。
-
-
-
-
-
-
-
-
-
搜索结果
32 条记录 (耗时 0.032 秒)
